SPRY · Company research
ARS Pharmaceuticals, Inc. Common Stock (SPRY): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 4.295 | $436,904,195.2 | 412583195.2 | 52.8750000000000000 | — | — | 19.2630040650764957 | 7.1263814706074248 | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.